Cardiff Oncology Reports Results of Onvansertib in P-Ib/II Trial for the Treatment of KRAS-Mutated Metastatic Colorectal Cancer

September 9, 2021 Auto Bot Clinical Trials, Trial 0

Shots:

  • The P-Ib/II trial evaluates the safety and preliminary efficacy of onvansertib + Folfiri and Avastin in 2L treatment of patients with KRAS-mutated mCRC
  • As of July 2, 2021, 42% patients achieved a partial response at RP2D (15 mg/m2 dose); confirmed PR (37%); ORR (5-13%); mPFS has not yet reached. Additionally, 38% patients achieved an initial PR who treated at all dose levels (12 mg/m2, 15 mg/m2, 18 mg/m2); confirmed PR (31%); mPFS (9.4mos.) across all response-evaluable patients
  • Additionally, partial responses were observed across different KRAS mutation variants. The combination is well-tolerated and showed the synergistic effect

Click here to read full press release/ article | Ref: Cardiff Oncology | Image: PharmaLive

The post Cardiff Oncology Reports Results of Onvansertib in P-Ib/II Trial for the Treatment of KRAS-Mutated Metastatic Colorectal Cancer first appeared on PharmaShots.